Segment disclosures

Company overview

LIGAND PHARMACEUTICALS INC

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

22 dimension combinations 147 retained observations 36 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Operating Segments · Contract Revenue · Ligand Core Business Segment

Consolidation Items · Product Or Service · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=lgnd:ContractRevenueMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-302762000 USD20220809Open filing evidence
2022-01-01 – 2022-06-3013723000 USD20220809Open filing evidence
2021-04-01 – 2021-06-307729000 USD20220809Open filing evidence
2021-01-01 – 2021-06-3015936000 USD20220809Open filing evidence

Operating Segments · Ligand Core Business Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember
PeriodValueUnitFiledEvidence
2022-07-01 – 2022-09-3059221000 USD20221108Open filing evidence
2022-01-01 – 2022-09-30145863000 USD20221108Open filing evidence
2022-04-01 – 2022-06-3050127000 USD20220809Open filing evidence
2022-01-01 – 2022-06-3086642000 USD20220809Open filing evidence
2021-07-01 – 2021-09-3059695000 USD20221108Open filing evidence
2021-01-01 – 2021-09-30185140000 USD20221108Open filing evidence
2021-04-01 – 2021-06-3078854000 USD20220809Open filing evidence
2021-01-01 – 2021-06-30125445000 USD20220809Open filing evidence

Operating Segments · Ligand Core Business Segment · Royalty

Consolidation Items · Statement Business Segments · Product Or Service

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember;srt:ProductOrServiceAxis=us-gaap:RoyaltyMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-3017820000 USD20220809Open filing evidence
2022-01-01 – 2022-06-3031252000 USD20220809Open filing evidence
2021-04-01 – 2021-06-308616000 USD20220809Open filing evidence
2021-01-01 – 2021-06-3015728000 USD20220809Open filing evidence

Contract Revenue · Operating Segments · Ligand Core Business Segment

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=lgnd:ContractRevenueMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember
PeriodValueUnitFiledEvidence
2022-07-01 – 2022-09-304017000 USD20221108Open filing evidence
2022-01-01 – 2022-09-3017740000 USD20221108Open filing evidence
2021-07-01 – 2021-09-308954000 USD20221108Open filing evidence
2021-01-01 – 2021-09-3024889000 USD20221108Open filing evidence

Contract Revenue · Ligand Core Business Segment · Operating Segments

Product Or Service · Statement Business Segments · Consolidation Items

Source dimensions srt:ProductOrServiceAxis=lgnd:ContractRevenueMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-3110961000 USD20220509Open filing evidence
2021-01-01 – 2021-03-318207000 USD20220509Open filing evidence

Contract Revenue · Omni Ab Technologies Segment · Operating Segments

Product Or Service · Statement Business Segments · Consolidation Items

Source dimensions srt:ProductOrServiceAxis=lgnd:ContractRevenueMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:OmniAbTechnologiesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-318915000 USD20220509Open filing evidence
2021-01-01 – 2021-03-318559000 USD20220509Open filing evidence

Material Sales Captisol Core · Ligand Core Business Segment · Operating Segments

Product Or Service · Statement Business Segments · Consolidation Items

Source dimensions srt:ProductOrServiceAxis=lgnd:MaterialSalesCaptisolCoreMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-316226000 USD20220509Open filing evidence
2021-01-01 – 2021-03-311253000 USD20220509Open filing evidence

Royalty · Operating Segments · Ligand Core Business Segment

Product Or Service · Consolidation Items · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:RoyaltyMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember
PeriodValueUnitFiledEvidence
2022-07-01 – 2022-09-3019255000 USD20221108Open filing evidence
2022-01-01 – 2022-09-3050507000 USD20221108Open filing evidence
2021-07-01 – 2021-09-3015648000 USD20221108Open filing evidence
2021-01-01 – 2021-09-3031376000 USD20221108Open filing evidence

Operating Segments · Cydex Pharmaceuticals Inc

Consolidation Items · Statement Business Segments

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:CydexPharmaceuticalsIncMember
PeriodValueUnitFiledEvidence
2015-07-01 – 2015-09-308816000 USD20151109Open filing evidence
2015-01-01 – 2015-09-3027630000 USD20151109Open filing evidence
2015-04-01 – 2015-06-3013218000 USD20150805Open filing evidence
2015-01-01 – 2015-06-3018814000 USD20150805Open filing evidence
2014-07-01 – 2014-09-308549000 USD20151109Open filing evidence
2014-01-01 – 2014-09-3022632000 USD20151109Open filing evidence
2014-04-01 – 2014-06-304916000 USD20150805Open filing evidence
2014-01-01 – 2014-06-3014083000 USD20150805Open filing evidence

Operating Segments · Ligand

Consolidation Items · Statement Business Segments

Source dimensions us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandMember
PeriodValueUnitFiledEvidence
2015-07-01 – 2015-09-308885000 USD20151109Open filing evidence
2015-01-01 – 2015-09-3023092000 USD20151109Open filing evidence
2015-04-01 – 2015-06-305200000 USD20150805Open filing evidence
2015-01-01 – 2015-06-3014206000 USD20150805Open filing evidence
2014-07-01 – 2014-09-306424000 USD20151109Open filing evidence
2014-01-01 – 2014-09-3018907000 USD20151109Open filing evidence
2014-04-01 – 2014-06-305692000 USD20150805Open filing evidence
2014-01-01 – 2014-06-3012483000 USD20150805Open filing evidence

Cydex

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=lgnd:CydexMember
PeriodValueUnitFiledEvidence
2012-07-01 – 2012-09-302667000 USD20121114Open filing evidence
2012-01-01 – 2012-09-306025000 USD20121114Open filing evidence
2012-04-01 – 2012-06-301813000 USD20121114Open filing evidence
2012-01-01 – 2012-06-303348000 USD20121114Open filing evidence
2011-07-01 – 2011-09-302450000 USD20121114Open filing evidence
2011-01-01 – 2011-09-308383000 USD20121114Open filing evidence

Cydex Pharmaceuticals Inc

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=lgnd:CydexPharmaceuticalsIncMember
PeriodValueUnitFiledEvidence
2015-01-01 – 2015-03-315596000 USD20150511Open filing evidence
2014-01-01 – 2014-12-3137364000 RestatedUSD20150223Open filing evidence
2014-07-01 – 2014-09-308549000 USD20141031Open filing evidence
2014-01-01 – 2014-09-3022632000 USD20141031Open filing evidence
2014-04-01 – 2014-06-304916000 USD20140805Open filing evidence
2014-01-01 – 2014-06-3014083000 USD20140805Open filing evidence
2014-01-01 – 2014-03-319167000 USD20150511Open filing evidence
2013-01-01 – 2013-12-3127537000 USD20150223Open filing evidence
2013-07-01 – 2013-09-308274000 USD20141031Open filing evidence
2013-01-01 – 2013-09-3019448000 USD20141031Open filing evidence
2013-04-01 – 2013-06-305760000 USD20140805Open filing evidence
2013-01-01 – 2013-06-3011174000 USD20140805Open filing evidence
2013-01-01 – 2013-03-315414000 USD20140507Open filing evidence
2012-01-01 – 2012-12-3111806000 USD20150223Open filing evidence
2012-07-01 – 2012-09-302667000 USD20131108Open filing evidence
2012-01-01 – 2012-09-306025000 USD20131108Open filing evidence
2012-04-01 – 2012-06-301813000 USD20130801Open filing evidence
2012-01-01 – 2012-06-303348000 USD20130801Open filing evidence
2012-01-01 – 2012-03-311535000 USD20130508Open filing evidence
2011-01-01 – 2011-12-3116247000 USD20130314Open filing evidence

Development And Licensing Of Biopharmaceutical Assets

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=lgnd:DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3078746000 USD20261030Open filing evidence
2026-01-01 – 2026-09-30194161000 USD20261030Open filing evidence
2026-04-01 – 2026-06-3063693000 USD20260807Open filing evidence
2026-01-01 – 2026-06-30115415000 USD20260807Open filing evidence
2026-01-01 – 2026-03-3151722000 USD20260508Open filing evidence
2025-01-01 – 2025-12-31268087000 USD20260227Open filing evidence
2025-07-01 – 2025-09-30115461000 USD20261030Open filing evidence
2025-01-01 – 2025-09-30208421000 USD20261030Open filing evidence
2025-04-01 – 2025-06-3047627000 USD20260807Open filing evidence
2025-01-01 – 2025-06-3092960000 USD20260807Open filing evidence
2025-01-01 – 2025-03-3145333000 USD20260508Open filing evidence
2024-01-01 – 2024-12-31167133000 USD20260227Open filing evidence
2024-07-01 – 2024-09-3051812000 USD20251107Open filing evidence
2024-01-01 – 2024-09-30124321000 USD20251107Open filing evidence
2024-04-01 – 2024-06-3041531000 USD20250808Open filing evidence
2024-01-01 – 2024-06-3072509000 USD20250808Open filing evidence
2024-01-01 – 2024-03-3130978000 USD20250509Open filing evidence
2023-01-01 – 2023-12-31131314000 USD20260227Open filing evidence
2022-01-01 – 2022-12-31196245000 USD20250228Open filing evidence

Ligand Core Business Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-3136515000 USD20220509Open filing evidence
2021-01-01 – 2021-03-3146591000 USD20220509Open filing evidence

Ligand Core Business Segment · Material Sales Captisol COVID · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember;srt:ProductOrServiceAxis=lgnd:MaterialSalesCaptisolCOVIDMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-315896000 USD20220509Open filing evidence
2021-01-01 – 2021-03-3130019000 USD20220509Open filing evidence

Ligand Core Business Segment · Royalty · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember;srt:ProductOrServiceAxis=us-gaap:RoyaltyMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-01-01 – 2022-03-3113432000 USD20220509Open filing evidence
2021-01-01 – 2021-03-317112000 USD20220509Open filing evidence

Ligand

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandMember
PeriodValueUnitFiledEvidence
2015-01-01 – 2015-03-319006000 USD20150511Open filing evidence
2014-01-01 – 2014-12-3127174000 RestatedUSD20150223Open filing evidence
2014-07-01 – 2014-09-306424000 USD20141031Open filing evidence
2014-01-01 – 2014-09-3018907000 USD20141031Open filing evidence
2014-04-01 – 2014-06-305692000 USD20140805Open filing evidence
2014-01-01 – 2014-06-3012483000 USD20140805Open filing evidence
2014-01-01 – 2014-03-316791000 USD20150511Open filing evidence
2013-01-01 – 2013-12-3121436000 USD20150223Open filing evidence
2013-07-01 – 2013-09-304731000 USD20141031Open filing evidence
2013-01-01 – 2013-09-3014789000 USD20141031Open filing evidence
2013-04-01 – 2013-06-303820000 USD20140805Open filing evidence
2013-01-01 – 2013-06-3010057000 USD20140805Open filing evidence
2013-01-01 – 2013-03-316237000 USD20140507Open filing evidence
2012-01-01 – 2012-12-3119582000 USD20150223Open filing evidence
2012-07-01 – 2012-09-303708000 USD20131108Open filing evidence
2012-01-01 – 2012-09-3011728000 USD20131108Open filing evidence
2012-04-01 – 2012-06-303929000 USD20130801Open filing evidence
2012-01-01 – 2012-06-308030000 USD20130801Open filing evidence
2012-01-01 – 2012-03-314101000 USD20130508Open filing evidence
2011-01-01 – 2011-12-3113790000 USD20130314Open filing evidence
2011-07-01 – 2011-09-303291000 USD20121114Open filing evidence
2011-01-01 – 2011-09-308718000 USD20121114Open filing evidence

Omni Ab Technologies Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=lgnd:OmniAbTechnologiesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-07-01 – 2022-09-306867000 USD20221108Open filing evidence
2022-01-01 – 2022-09-3023337000 USD20221108Open filing evidence
2022-04-01 – 2022-06-307292000 USD20220809Open filing evidence
2022-01-01 – 2022-06-3016470000 USD20220809Open filing evidence
2022-01-01 – 2022-03-319178000 USD20220509Open filing evidence
2021-07-01 – 2021-09-305140000 USD20221108Open filing evidence
2021-01-01 – 2021-09-3019520000 USD20221108Open filing evidence
2021-04-01 – 2021-06-305821000 USD20220809Open filing evidence
2021-01-01 – 2021-06-3014380000 USD20220809Open filing evidence
2021-01-01 – 2021-03-318559000 USD20220509Open filing evidence

Omni Ab Technologies Segment · Operating Segments · Contract Revenue

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=lgnd:OmniAbTechnologiesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=lgnd:ContractRevenueMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-307153000 USD20220809Open filing evidence
2022-01-01 – 2022-06-3016068000 USD20220809Open filing evidence
2021-04-01 – 2021-06-305821000 USD20220809Open filing evidence
2021-01-01 – 2021-06-3014380000 USD20220809Open filing evidence

Omni Ab Technologies Segment · Operating Segments · Royalty

Statement Business Segments · Consolidation Items · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=lgnd:OmniAbTechnologiesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=us-gaap:RoyaltyMember
PeriodValueUnitFiledEvidence
2022-04-01 – 2022-06-30139000 USD20220809Open filing evidence
2022-01-01 – 2022-06-30402000 USD20220809Open filing evidence
2021-04-01 – 2021-06-300 USD20220809Open filing evidence
2021-01-01 – 2021-06-300 USD20220809Open filing evidence

Omni Ab Technologies Segment · Contract Revenue · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=lgnd:OmniAbTechnologiesSegmentMember;srt:ProductOrServiceAxis=lgnd:ContractRevenueMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-07-01 – 2022-09-306285000 USD20221108Open filing evidence
2022-01-01 – 2022-09-3022353000 USD20221108Open filing evidence
2021-07-01 – 2021-09-305140000 USD20221108Open filing evidence
2021-01-01 – 2021-09-3019520000 USD20221108Open filing evidence

Omni Ab Technologies Segment · Royalty · Operating Segments

Statement Business Segments · Product Or Service · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=lgnd:OmniAbTechnologiesSegmentMember;srt:ProductOrServiceAxis=us-gaap:RoyaltyMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2022-07-01 – 2022-09-30582000 USD20221108Open filing evidence
2022-01-01 – 2022-09-30984000 USD20221108Open filing evidence
2022-01-01 – 2022-03-31263000 USD20220509Open filing evidence
2021-07-01 – 2021-09-300 USD20221108Open filing evidence
2021-01-01 – 2021-09-300 USD20221108Open filing evidence
2021-01-01 – 2021-03-310 USD20220509Open filing evidence